Meet Inspiring Speakers and Experts at our 3000+ Global Conference Series Events with over 1000+ Conferences, 1000+ Symposiums
and 1000+ Workshops on Medical, Pharma, Engineering, Science, Technology and Business.

Explore and learn more about Conference Series : World's leading Event Organizer

Back

Carlos Modenutti

Carlos Modenutti

Universidad de Buenos Aires, Argentina

Title: From sequence to 3D-model: an efficient use of homology modeling, molecular dynamics and ligand docking techniques to predict protein-carbohydrate complexes

Biography

Biography: Carlos Modenutti

Abstract

Proteins that bind carbohydrates are responsible for numerous important biological functions, such as signal transduction, cell adhesion, among many others. Despite the number of reported structures of protein-carbohydrates complexes (PCCs) is constantly increasing, achieving accurate predictions of the protein-carbohydrate interaction by means of Structural Homology Models (SHM) and ligand-docking remains one of the biggest challenges in Glycobiology. This is due mainly because the residues that form the Carbohydrate Binding Site (CBS) can differ from its ideal binding rotamer in the SHM, which can thereafter significantly affect Docking algorithms performance. In addition, while generally available docking programs work reasonably well for most drug-like compounds, carbohydrates and carbohydrate-like molecules are often problematic, because Force-Fields and Scoring Functions are typically designed to reproduce structures of protein-drug complexes. In this work, we present an integrated approach that combines conformational-space sampling of SHM using Molecular Dynamics simulations (MD) and Docking experiments. In order to obtain the most plausible binding structure of receptor and ligand, clustering analysis to identify different conformations was applied. Finally, Water-Site Bias Docking Method (WSBDM, an Autodock based protocol) was performed to generate a diversity of structures and energy-population parameters are used to rank each one of them. Here, we used human Pulmonary Surfactant-associated protein D (hSP-D) as a case study. The results show that this emerges as a promising tool to build reliable 3D-models, which can then be used for rational design or optimization of glycomimetic drugs.